Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.

MLA

Liu, Man‐Yu, et al. “Selective and Effective Targeting of Chronic Myeloid Leukemia Stem Cells by Topoisomerase II Inhibitor Etoposide in Combination with Imatinib Mesylate in Vitro.” Cell Biology International, vol. 41, no. 1, Jan. 2017, pp. 16–23. EBSCOhost, https://doi.org/10.1002/cbin.10686.

APA

Liu, M., Wang, W., Liao, F., Wu, Q., Lin, X., Chen, Y., Cheng, L., Jin, X., & Zhu, J. (2017). Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro. Cell Biology International, 41(1), 16–23. https://doi.org/10.1002/cbin.10686

Chicago

Liu, Man‐Yu, Wei‐Zhang Wang, Fen‐Fang Liao, Qing‐Qing Wu, Xiang‐Hua Lin, Yong‐Hen Chen, Lin Cheng, Xiao‐Bao Jin, and Jia‐Yong Zhu. 2017. “Selective and Effective Targeting of Chronic Myeloid Leukemia Stem Cells by Topoisomerase II Inhibitor Etoposide in Combination with Imatinib Mesylate in Vitro.” Cell Biology International 41 (1): 16–23. doi:10.1002/cbin.10686.